Wednesday, May 08, 2024 The MA40 trial, a double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor has closed to further accrual as the accrual target of 250 study participants enrolled. Patients were enrolled and received either Ipatasertib plus Fulvestrant or placebo plus Fulvestant. The study provided information about the ability of Ipatasertib plus Fulvestrant to control the cancer, the side effects and safety of the treatment, how patients feel while taking the treatment and associated costs.For more information please visit the CCTG MA40 members study page.
